Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 65Neoplasms 31Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 24Melanoma 23Colorectal Neoplasms 23Triple Negative Breast Neoplasms 20Carcinoma, Renal Cell 20Carcinoma, Transitional Cell 19Breast Neoplasms 18Neoplasm Metastasis 14Urinary Bladder Neoplasms 13Stomach Neoplasms 12Uterine Cervical Neoplasms 11Solid Tumors 11Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 8Lymphoma 7Lung Neoplasms 7Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Esophageal Neoplasms 6Pancreatic Neoplasms 5Liver Neoplasms 5Carcinoma, Merkel Cell 5Advanced Solid Tumor 5Solid Tumor 4Prostatic Neoplasms 4Leukemia, Myeloid, Acute 4Kidney Neoplasms 4

Interventions

atezolizumab 2Hydroxyurea 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Treatment-Refractory Solid Tumors × atezolizumab × Clear all
NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Bionoxx Inc.

Phase 1 Recruiting
27 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡